Reconnecting

The current page stays visible while onset.to reconnects in the background.

U.S. backs Mark Cuban's company to develop ibogaine for PTSD and opens $20 million call for psychedelics evidence network

Open original

The U.S. government is backing Mark Cuban Cost Plus Drug Company to develop ibogaine for PTSD and has opened a $20 million funding opportunity for a real-world psychedelics research network. HHS said ARPA-H would commit up to $4.9 million to the ibogaine effort, undertaken in collaboration with the Department of Veterans Affairs. The company will develop regulatory and manufacturing processes, and ARPA-H has acquired data from ibogaine clinic operator Beond to support the work. The research network funding opportunity is housed at the National Institute of Mental Health.